Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?
Executive Summary
The hemophilia market could be about to undergo a wave of innovation not seen since the introduction of recombinant factor 20 years ago in response to a crisis in contaminated plasma products. Over the next three years, long-acting factor products may have an even more transformative effect on the market, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. But will the improvements be enough to sway providers and payors?